Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma
Authors:
- 11 October 2022
- journal article
- research article
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 41 (2) , 209-218
Abstract
Purpose This study aimed to investigate the value of metabolic and heterogeneity parameters of 2-deoxy-2[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in predicting epidermal growth factor receptor (EGFR) mutations in patients with lung adenocarcinoma (ADC). Materials and methods A retrospective analysis was performed on 157 patients with lung ADC between September 2015 and June 2021, who had undergone both EGFR mutation testing and [18F]FDG PET/CT examination. Metabolic and heterogeneity parameters were measured and calculated, including maximum diameter (Dmax), maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity factor (HF). Relationships between PET/CT parameters and EGFR mutation status were evaluated and a multivariate logistic regression analysis was analyzed to establish a combined prediction model. Results 108 (68.8%) patients exhibited EGFR mutations. EGFR mutations were more likely to occur in females (51.9% vs. 48.1%, P = 0.007), non-smokers (83.3% vs. 16.7%, P < 0.001) and right lobes (55.6% vs. 44.4%, P = 0.017). High Dmax, MTV and HF and low SUVmean were significantly correlated with EGFR mutations, and the areas under the ROC curve (AUCs) measuring 0.647, 0.701, 0.757, and 0.661, respectively. Multivariate logistic regression analysis suggested that non-smokers (OR = 0.30, P = 0.034), low SUVmean (≤ 7.75, OR = 0.63, P < 0.001) and high HF (≥ 4.21, OR = 1.80, P = 0.027) were independent predictors of EGFR mutations. The AUC of the combined prediction model measured up to 0.863, significantly higher than that of a single parameter. Conclusions EGFR mutant in lung ADC patients showed more intratumor heterogeneity (HF) than EGFR wild type, which was combined clinical feature (non-smokers), and metabolic parameter (SUVmean) may be helpful in predicting EGFR mutation status, thus playing a guiding role in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) targeted therapies.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (WK9110000061)
This publication has 42 references indexed in Scilit:
- Contribution of18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinomaCancer Biomarkers, 2016
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- FDG Uptake in Non–Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation StatusClinical Nuclear Medicine, 2015
- Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung CancerClinical Nuclear Medicine, 2015
- Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 2014
- FDG‐PET SUV‐max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinomaRespirology, 2013
- Nasopharyngeal Carcinoma: Investigation of Intratumoral Heterogeneity With FDG PET/CTAmerican Journal of Roentgenology, 2012
- Quantifying heterogeneity in human tumours using MRI and PETEuropean Journal of Cancer, 2012
- Biological significance of the maximum standardized uptake values on positron emission tomography in non‐small cell lung cancerJournal of Surgical Oncology, 2009